COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00066326
Recruitment Status : Completed
First Posted : August 7, 2003
Last Update Posted : April 5, 2013
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Barbara Ann Karmanos Cancer Institute

Brief Summary:

RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Drugs used in chemotherapy such as 17-N-allylamino-17-demethoxygeldanamycin use different ways to stop cancer cells from dividing so they stop growing or die. Combining imatinib mesylate with chemotherapy may kill more cancer cells.

PURPOSE: This phase I trial is studying the side effects and best dose of 17-N-allylamino-17-demethoxygeldanamycin when given together with imatinib mesylate in treating patients with chronic myelogenous leukemia.

Condition or disease Intervention/treatment Phase
Leukemia Drug: imatinib mesylate Drug: tanespimycin Phase 1

Detailed Description:


  • Determine the maximum tolerated dose and dose-limiting toxicity of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG) when administered with imatinib mesylate in patients with chronic myelogenous leukemia.
  • Determine the pharmacokinetics of this regimen in these patients.

OUTLINE: This is an open-label, nonrandomized, multicenter, dose-escalation study of 17-N-allylamino-17-demethoxygeldanamycin (17-AAG).

Patients receive oral imatinib mesylate on days 1-21 and 17-AAG IV over 1 hour on days 1, 4, 8, and 12. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of 17-AAG until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, an additional cohort of 6-10 patients receives treatment at the recommended phase II dose.

PROJECTED ACCRUAL: Approximately 21-42 patients will be accrued for this study within 1.5 years.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase I Study Of The Combination Of 17-AAG And Imatinib Mesylate (Gleevec) In Patients With Blastic Phase, Accelerated Phase Of Chronic Mesylate Leukemia (CML) Or Patients With Chronic Phase CML Who Have Not Achieved A Cytogenetic Response With Imatinib Mesylate
Study Start Date : June 2003
Actual Primary Completion Date : October 2004
Actual Study Completion Date : September 2005

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Diagnosis of chronic myelogenous leukemia, including any of the following phases:

    • Blastic phase

      • Greater than 30% blasts in the peripheral blood or bone marrow
      • Previously untreated disease OR refractory to or relapsed after most recent therapy
    • Accelerated phase, defined by 1 of the following:

      • At least 15, but less than 30%, blasts in the peripheral blood or bone marrow
      • At least 30% blasts and promyelocytes in the peripheral blood or bone marrow
      • Greater than 20% peripheral blood basophilia
    • Chronic phase

      • No major cytogenetic response (less than 65% Philadelphia chromosome negative) after 12 months of prior imatinib mesylate therapy
  • Philadelphia chromosome positive by routine cytogenetics



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 3 months


  • Not specified


  • Bilirubin no greater than 1.5 mg/dL
  • ALT and AST no greater than 2.5 times upper limit of normal


  • Creatinine less than 1.5 mg/dL


  • No symptomatic congestive heart failure
  • No unstable angina pectoris
  • No cardiac arrhythmia


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No known allergy to eggs
  • Able to swallow pills
  • No ongoing or active infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No other concurrent uncontrolled medical illness


Biologic therapy

  • No prior stem cell transplantation


  • More than 4 weeks since prior chemotherapy (except hydroxyurea or anagrelide) (at least 6 weeks for nitrosoureas or mitomycin)

Endocrine therapy

  • Not specified


  • More than 4 weeks since prior radiotherapy


  • No prior liver, kidney, or lung transplantation
  • More than 14 days since prior major surgery (e.g., thoracotomy or intra-abdominal surgery)


  • Prior imatinib mesylate administered within the past 4 weeks is allowed
  • No concurrent tacrolimus or cyclosporine as immunosuppressive agents
  • No other concurrent investigational agents
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • No concurrent agents that alter CYP3A4 activity, including any of the following:

    • Grapefruit juice
    • Ketoconazole
    • Fluconazole
    • Itraconazole
    • Erythromycin
    • Clarithromycin
    • Cimetidine
    • Terfenadine
    • Astemizole
    • HIV protease inhibitors (e.g., indinavir and nelfinavir)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00066326

Layout table for location information
United States, Michigan
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, United States, 48201-1379
Sponsors and Collaborators
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Layout table for investigator information
Study Chair: Charles A. Schiffer, MD Barbara Ann Karmanos Cancer Institute
Layout table for additonal information
Responsible Party: Barbara Ann Karmanos Cancer Institute Identifier: NCT00066326    
Other Study ID Numbers: CDR0000315521
U01CA062487 ( U.S. NIH Grant/Contract )
P30CA022453 ( U.S. NIH Grant/Contract )
First Posted: August 7, 2003    Key Record Dates
Last Update Posted: April 5, 2013
Last Verified: April 2013
Keywords provided by Barbara Ann Karmanos Cancer Institute:
blastic phase chronic myelogenous leukemia
Philadelphia chromosome positive chronic myelogenous leukemia
chronic phase chronic myelogenous leukemia
accelerated phase chronic myelogenous leukemia
relapsing chronic myelogenous leukemia
Additional relevant MeSH terms:
Layout table for MeSH terms
Leukemia, Myeloid
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Neoplasms by Histologic Type
Myeloproliferative Disorders
Bone Marrow Diseases
Hematologic Diseases
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action